Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

NCT02452697 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Myeloid Malignancies
Lymphoid Malignancies

Interventions

BIOLOGICAL: NK Cell enriched-DLI only
BIOLOGICAL: NK-DLI + DUK-CPG-001

Sponsor

Cristina Gasparetto

Collaborators

[object Object]